Related Experiment Video
Updated: Sep 13, 2025
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
Leveraging DNA repair deficiency to personalize radiopharmaceutical therapy in prostate cancer
1Department of Medical Oncology, IASO Thessalias Hospital, Larissa, Greece; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY.
Abstract:
Radiopharmaceutical therapies targeting prostate-specific membrane antigen (PSMA) have transformed the management of metastatic prostate cancer, yet inter-patient variability in therapeutic response remains a critical challenge. Emerging evidence indicates that defects in DNA repair pathways, including homologous recombination deficiency (HRD) and mismatch repair deficiency (MMRd), sensitize tumor cells to ionizing radiation by impairing damage resolution. Ongoing research explores the potential of integrating genomic profiling of DNA repair defects to optimize patient selection and personalize radiopharmaceutical strategies such as 177Lu-PSMA and alpha-emitting conjugates. Clinical efforts to combine targeted radiation with synthetic lethality approaches are ongoing. Tailoring radiopharmaceutical therapy to individual tumor DNA repair profiles offers a promising paradigm to improve outcomes and expand therapeutic windows in advanced prostate cancer.
Insights
Personalizing prostate cancer radiopharmaceutical therapy by analyzing DNA repair defects can improve patient outcomes. Genomic profiling of homologous recombination deficiency and mismatch repair deficiency guides treatment selection for advanced disease.
Area of Science:
- Oncology
- Radiopharmaceutical Therapy
- Genomics
Background:
- Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals have advanced metastatic prostate cancer treatment.
- Significant inter-patient variability in treatment response necessitates personalized approaches.
Discussion:
- Defects in DNA repair pathways (homologous recombination deficiency [HRD] and mismatch repair deficiency [MMRd]) sensitize cancer cells to radiation.
- Genomic profiling of these defects can identify patients likely to benefit from specific radiotherapies.
- Combining targeted radiation with synthetic lethality strategies is under investigation.
Key Insights:
- Integrating DNA repair defect status into patient selection optimizes radiopharmaceutical therapy.
- Personalized strategies enhance therapeutic efficacy and broaden treatment windows.
- 177Lu-PSMA and alpha-emitting conjugates show promise when tailored to tumor biology.
Outlook:
- Tailoring radiopharmaceutical therapy to individual tumor DNA repair profiles represents a promising paradigm shift.
- Further research will refine patient stratification and treatment protocols.
- This approach holds potential for improved outcomes in advanced prostate cancer.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
06:44Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:38Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...